Pfizer Inc. (NYSE:PFE) Shares Sold by Prudential PLC

Prudential PLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 525,317 shares of the biopharmaceutical company's stock after selling 21,204 shares during the quarter. Prudential PLC's holdings in Pfizer were worth $13,937,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in PFE. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Pfizer in the fourth quarter worth approximately $274,694,000. Massachusetts Financial Services Co. MA raised its holdings in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after acquiring an additional 4,938,209 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock traded down $0.38 during mid-day trading on Tuesday, hitting $22.25. The company had a trading volume of 27,770,938 shares, compared to its average volume of 39,603,031. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company's fifty day moving average is $25.79 and its 200-day moving average is $26.67. Pfizer Inc. has a 12-month low of $21.75 and a 12-month high of $31.54. The company has a market capitalization of $126.18 billion, a price-to-earnings ratio of 15.78, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The company's quarterly revenue was up 24.7% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.